AKT1 and breast carcinoma: More importantly, we present a combination strategy of STING agonists and AKT1 inhibitors that could block the positive feedback loop to maximize the activation of cGAS‐STING signaling in endocrine‐resistant breast cancer cells, overcoming endocrine resistance.